Top-News

Immune Pharmaceuticals News

Keine aktuellen Kursdaten verfügbar
WKN: A2DQB0
ISIN: US45254C2008
US-Symbol: IMNPQ
Typ: Aktie

Immune Pharmaceuticals News

29.03.21 - ACCESSWIRE
Acquisition of Immune Pharmaceuticals
Unconditional offer in relation to acquire the public entity
18.03.21 - ACCESSWIRE
Immune Pharmaceuticals Inc Announces Immune Pharmaceuticals Proposal to Exit Bankruptcy
Immune Pharmaceuticals, Inc. (IMNPQ) Proposal to Exit Bankruptcy.
05.07.17 - PR Newswire
IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia,
IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients ...
29.06.17 - PR Newswire
Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of
Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the ...
20.06.17 - PR Newswire
Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)
Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) Immune's subsidiary, ...
19.06.17 - PR Newswire
Immune Receives NASDAQ Compliance Letter
Immune Receives NASDAQ Compliance Letter PR Newswire
15.06.17 - PR Newswire
Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene
Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene Immune's subsidiary, Cytovia, plans commercialization activities in Europe and Latin America ...
26.05.17 - PR Newswire
Immune Receives Nasdaq Letters
Immune Receives Nasdaq Letters PR Newswire
24.04.17 - PR Newswire
Immune Pharmaceuticals Announces Corporate Restructuring
Immune Pharmaceuticals Announces Corporate Restructuring - Inflammatory disease and dermatology business to become the focus of Immune Pharmaceuticals, Inc., with ...
24.04.17 - PR Newswire
Immune Receives Nasdaq Letter
Immune Receives Nasdaq Letter PR Newswire
20.04.17 - PR Newswire
Immune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene® in Latin America
Immune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene® in Latin America PR Newswire
12.04.17 - PR Newswire
Immune Pharmaceuticals Announces 1-for-20 Reverse Stock Split
Immune Pharmaceuticals Announces 1-for-20 Reverse Stock Split PR Newswire
13.03.17 - PR Newswire
Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement
Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement PR Newswire
28.02.17 - PR Newswire
Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid
Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-​Immune Disease, Bullous ...
17.02.17 - PR Newswire
Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia
Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute ...
06.02.17 - PR Newswire
Purcell Julie & Lefkowitz LLP Is Investigating Immune Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP Is Investigating Immune Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
27.01.17 - PR Newswire
Immune Pharmaceuticals Appoints New Chairman of the Board of Directors
Immune Pharmaceuticals Appoints New Chairman of the Board of Directors Ranch Kimball to Lead Immune's Board of Directors PR Newswire
23.01.17 - PR Newswire
Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment
Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment PR Newswire
09.01.17 - PR Newswire
Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq's Minimum Bid Price Rule
Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq's Minimum Bid Price Rule PR Newswire
22.11.16 - PR Newswire
Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016
Immune Pharmaceuticals Announces Immuno-​Oncology R&D Update on December 8, 2016 Confirms plans for pivotal phase 3 Overall Survival study with Ceplene in AML PR ...

Newssuche

Videos

newspaper
09:30 Uhr +21,95%
Technical Trading: S&P 500 Short Chance
S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »